» Articles » PMID: 9285564

Identification of an Additional P53-responsive Site in the Human Epidermal Growth Factor Receptor Gene Promotor

Overview
Journal Oncogene
Date 1997 Aug 28
PMID 9285564
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-deficient Saos2 osteosarcoma cells. A p53 binding site residing at position -265/-239 in the EGF-R proximal promoter has also been identified. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53Ala143 enhanced the EGF-R core promotor activity in cells that were either p53-deficient or contained wild-type or mutant endogenous p53. Upon further characterization of the various deletion fragments of the EGF-R promoter, we identified a wild-type p53 responsive 62 bp region residing at position -167/-105. The -167/-105 segment was responsive only to wild-type p53 but not to mutant p53Ala143 or p53His273. The -167/-105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp -167/-105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Thus, we have identified an additional wild-type p53 responsive site in the human EGF-R promoter. This site containing consensus p53-binding sequences resides at position -167/-105 and is proximal to recently identified p53 binding element located at position -265/-239 in the EGF-R promotor.

Citing Articles

Secreted Cytokines within the Urine of AKI Patients Modulate TP53 and SIRT1 Levels in a Human Podocyte Cell Model.

Erichsen L, Thimm C, Wruck W, Kaierle D, Schless M, Huthmann L Int J Mol Sci. 2023; 24(9).

PMID: 37175937 PMC: 10179415. DOI: 10.3390/ijms24098228.


RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma.

Bai X, Zhang C, Peng R, Jiang G, Jin S, Wang Q Onco Targets Ther. 2020; 13:10129-10141.

PMID: 33116595 PMC: 7553654. DOI: 10.2147/OTT.S269606.


RNF128 Promotes Invasion and Metastasis Via the EGFR/MAPK/MMP-2 Pathway in Esophageal Squamous Cell Carcinoma.

Gao J, Wang Y, Yang J, Zhang W, Meng K, Sun Y Cancers (Basel). 2019; 11(6).

PMID: 31216681 PMC: 6627419. DOI: 10.3390/cancers11060840.


Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.

de Almeida V, Melo A, Meira D, Pires A, Nogueira-Rodrigues A, Pimenta-Inada H Braz J Med Biol Res. 2017; 51(1):e6822.

PMID: 29160417 PMC: 5685065. DOI: 10.1590/1414-431X20176822.


Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".

Purba E, Saita E, Maruyama I Cells. 2017; 6(2).

PMID: 28574446 PMC: 5492017. DOI: 10.3390/cells6020013.